Clinical Trial

Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Name: Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia — clinical trial record (NCT07342244)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).

Trial Details

NCT Number	NCT07342244
Lead Sponsor	Donghua Zhang
Conditions	AML, AML (Acute Myeloid Leukemia)
Enrollment	18 participants
Start Date	2026-01-30
Primary Completion	2028-12-20 (estimated)
Study Completion	2029-12-20 (estimated)
Updated on ClinicalTrials.gov	2026-01-15